Last reviewed · How we verify
NCT05048706
SP TLF Versus Ho:YAG Laser
trial testing Laser lithotripsy (SP TLF) in Urinary Calculi in 62 participants. Completed in 1 January 2024.
1 January 2024
Quick facts
| Lead sponsor | University of Rochester |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 62 |
| Start date | 10 May 2021 |
| Primary completion | 1 January 2024 |
| Estimated completion | 1 January 2024 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Laser lithotripsy (SP TLF)
- Laser lithotripsy (Ho:YAG)
Conditions studied
- Urinary Calculi — all drugs for Urinary Calculi →
Sponsor
University of Rochester
Who can join
18 and older, any sex, with Urinary Calculi. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators aim to compare the performance of the Super Pulse Thulium fiber laser (SP TFL) with that of the standard Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) laser. The investigators hypothesize that the electronically-modulated laser diodes, of the TFL offers the most comprehensive and flexible range of laser parameters among laser lithotripters leading to more efficient (4 times more) and effective stone dusting resulting in production of finer dust particles obviating the need for postoperative ureteric stenting which remains a major source of patient discomfort.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05048706
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urinary Calculi
Currently open trials in the same condition.
- NCT06519812 — Endoscopic Combined Intrarenal Surgery vs. Percutaneous Nephrolithotomy for Treatment of Staghorn Calculi · NA · recruiting
- NCT04796792 — Ultrasound to Facilitate Stone Passage · NA · recruiting
- NCT05574517 — Tubeless Percutaneous Nephrolithotomy Without Reverse Insertion of a Ureteral Catheter · NA · recruiting
- NCT05712785 — Shuotongo Ureteroscopy for Upper Urinary Tract Stones · NA · recruiting
- NCT03811171 — Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study · NA · recruiting
Other University of Rochester trials
Trials by the same sponsor.
- NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
- NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
- NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
- NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
- NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05048706 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rochester
- Last refreshed: 24 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05048706.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing